Trial Profile
Efficacy of darunavir/ritonavir used as monotherapy at a low dose (600/100 mg/day) in virologically suppressed HIV-infected patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Darunavir/ritonavir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 19 Dec 2017 New trial record
- 05 Dec 2017 Results published in the Journal of Antimicrobial Chemotherapy.